Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade C 11.93 0.59% 0.07
CCXI closed up 0.34 percent on Tuesday, May 21, 2019, on 1.22 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical CCXI trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.59%
Narrow Range Bar Range Contraction 0.59%
NR7 Range Contraction 0.59%
Gapped Down Weakness 0.93%
20 DMA Resistance Bearish -4.02%
Fell Below 50 DMA Bearish -4.02%
Shooting Star Candlestick Bearish -4.02%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.02%
Narrow Range Bar Range Contraction -4.02%
NR7 Range Contraction -4.02%

Older signals for CCXI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Medicine Biopharmaceutical Cancer Immunology Autoimmune Diseases Monoclonal Antibodies Rheumatoid Arthritis Inflammatory Bowel Disease Immunosuppressants Atopic Dermatitis Diabetic Nephropathy Glioblastoma Multiforme Kidney Disease Biotie Therapies Dermatitis Inflammatory Disorders Inflammatory Disease Janus Kinase Inhibitor Chemo
Is CCXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.98
52 Week Low 9.07
Average Volume 575,517
200-Day Moving Average 11.5001
50-Day Moving Average 12.5576
20-Day Moving Average 12.611
10-Day Moving Average 12.164
Average True Range 0.5913
ADX 23.07
+DI 15.8527
-DI 30.1253
Chandelier Exit (Long, 3 ATRs ) 12.0161
Chandelier Exit (Short, 3 ATRs ) 13.4039
Upper Bollinger Band 13.6458
Lower Bollinger Band 11.5762
Percent B (%b) 0.14
BandWidth 16.41107
MACD Line -0.1987
MACD Signal Line -0.1047
MACD Histogram -0.094
Fundamentals Value
Market Cap 577.65 Million
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -19.13
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.19
Resistance 3 (R3) 12.20 12.10 12.14
Resistance 2 (R2) 12.10 12.02 12.10 12.12
Resistance 1 (R1) 11.98 11.96 11.93 11.97 12.10
Pivot Point 11.88 11.88 11.86 11.88 11.88
Support 1 (S1) 11.76 11.80 11.71 11.75 11.62
Support 2 (S2) 11.66 11.74 11.66 11.60
Support 3 (S3) 11.54 11.66 11.59
Support 4 (S4) 11.53